Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys

Nucleic Acid Therapeutics

Volumn 23, Issue 3, 2013, Pages 213-227

  Burel, Sebastien A ^a   Han, So Ri ^b   Lee, Hong Soo ^b   Norris, Daniel A ^a   Lee, Byoung Seok ^b   MacHemer, Todd ^a   Park, Shin Young ^b   Zhou, Tianyuan ^a   He, Guobin ^a   Kim, Youngsoo ^a   MacLeod, A Robert ^a   Monia, Brett P ^a   Lio, Shirley ^a   Kim, Tae Won ^a   Henry, Scott P ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b Korea Institute of Toxicology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANTISENSE OLIGONUCLEOTIDE; ASPARTATE AMINOTRANSFERASE; COMPLEMENT COMPONENT BB; INTERLEUKIN 10; ISIS 481464; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOROTHIOIC ACID DERIVATIVE; STAT3 PROTEIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SCREENING; EXPERIMENTAL MONKEY; FEMALE; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE DAMAGE; KIDNEY TUBULE EPITHELIUM; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; REGENERATION; SPLEEN WEIGHT; TOXICITY TESTING; WEIGHT GAIN;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; KIDNEY; LIVER; MACACA FASCICULARIS; MALE; MICE; OLIGONUCLEOTIDES, ANTISENSE; ORGAN SIZE; PARTIAL THROMBOPLASTIN TIME; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; SPLEEN; STAT3 TRANSCRIPTION FACTOR;

EID: 84878247636     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2013.0422     Document Type: Article

References (36)

1. ACKERMANN, E.J., GUO, S., BOOTEN, S., ALVARADO, L., BENSON, M., HUGHES, S., and MONIA, B.P. (2012). Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19, 43-44.
2. AKDIM, F., STROES, E.S., SIJBRANDS, E.J., TRIBBLE, D.L., TRIP, M.D., JUKEMA, J.W., FLAIM, J.D., SU, J., YU, R., BAKER, B.F., et al. (2010). Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholester-olemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol. 55, 1611-1618.
3. ALVAREZ, J.V., FEBBO, P.G., RAMASWAMY, S., LODA, M., RICHARDSON, A., and FRANK, D.A. (2005). Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 65, 5054-5062.
4. BODE, J.G., ALBRECHT, U., HAUSSINGER, D., HEINRICH, P.C., and SCHAPER, F. (2012). Hepatic acute phase proteins-regulation by IL-6-and IL-1-type cytokines involving STAT3 and its crosstalk with NF-kappaB-dependent signaling. Eur. J. Cell Biol. 91, 496-505.
5. BUTLER, A.M., and MURRAY, M. (1997). Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation. J. Pharmacol. Exp. Ther. 280, 966-973.
6. CHI, K.N., EISENHAUER, E., FAZLI, L., JONES, E.C., GOLDENBERG, S.L., POWERS, J., TU, D., and GLEAVE, M.E. (2005). A phase 1 pharmacokinetic and pharmacodynamic study of OGX-011, a 2¢-methoxyethyl antisense oligonucleo-tide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. 97, 1287-1296.
7. CHIANG, M.-Y., CHAN, H., ZOUNES, M.A., FREIER, S.M., LIMA, W.F., and BENNETT, C.F. (1991). Antisense oligonu-cleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266, 18162-18171.
8. CROOKE, S.T., VICKERS, T., LIMA, W., and WU, H. (2007). Me-chanismsofAntisenseDrugAction, anIntroduction.In:Antisense Drug Technology, Principles, strategies and applications. S.T. Crooke, ed. (Taylor & Francis Group, Boca Raton, FL), pp5-46.
9. FARMAN, C.A., and KORNBRUST, D.J. (2003). Oligodeoxy-nucleotide studies in primates: antisense and immune stimulatory indications. Toxicol. Pathol. 31, 119122.
10. GEARY, R.S., YU, R.Z., SIWKOWSKI, A., and LEVIN, A.A. (2007). Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2¢-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man. In: Antisense Drug Technology, Principles, strategies and applications. S.T. Crooke, ed. (Taylor & Francis Group, Boca Raton, FL), pp 305-326.
11. HENRY, S.P., BEATTIE, G., YEH, G., CHAPPEL, A., GICLAS, P.C., MORTARI, A., JAGELS, M.A., KORNBRUST, D.J., and LEVIN, A.A. (2002). Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphoro-thioate oligodeoxynucleotide. Int. J Immunopharmacol. 2, 1657-1666.
12. HENRY, S.P., BOLTE, H., AULETTA, C., and KORNBRUST, D.J. (1997a). Evaluation of the toxicity of ISIS 2302, a phosphoro-thioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 120, 145-155.
13. HENRY, S.P., GEARY, R.S., YU, R., and LEVIN, A.A. (2001). Drug properties of second-generation antisense oligonucleo-tides: how do they measure up to their predecessors? Curr. Opin. Invest. Drugs 2, 1444-1449.
14. HENRY, S.P., GICLAS, P.C., LEEDS, J., PANGBURN, M., AU-LETTA, C., LEVIN, A.A., and KORNBRUST, D.J. (1997b). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J. Pharmacol. Exp. Ther. 281, 810-816.
15. HENRY, S.P., JAGELS, M., HUGLI, T., and GICLAS, P. (2000a). Species and pathway-specific activation of complement by a phosphorothioate oligonucleotide. Elsevier, ScienceDirect. Immunopharmacology 49, 97.
16. HENRY, S.P., JOHNSON, M., ZANARDI, T.A., FEY, R., AUYEUNG, D., LAPPIN, P.B., and LEVIN, A.A. (2012). Renal uptakeandtolerabilityofa2¢-O- methoxyethylmodifiedantisense oligonucleotide (ISIS 113715) in monkey. Toxicology 301, 13-20.
17. HENRY, S.P., KIM, T.-W., KRAMER-STICKLAND, K., ZA-NARDI, T.A., FEY, R.A., and LEVIN, A.A. (2007). Toxicologic properties of 2¢-o-methoxyethyl chimeric antisense inhibitors in animals and man. In Antisense Drug Technology, Principles, strategies and applications. S.T. Crooke, ed. (Taylor & Francis Group, Boca Raton, FL), pp 327-364.
18. HENRY, S.P., NOVOTNY, W., LEEDS, J., AULETTA, C., and KORNBRUST, D.J. (1997c). Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense and Nucleic Acid Drug Dev. 7, 503-510.
19. HENRY, S.P., STECKER, K., BROOKS, D., MONTEITH, D., CONKLIN, B., and BENNETT, C.F. (2000b). Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 292, 468-479.
20. HENRY, S.P., TAYLOR, J., MIDGLEY, L., LEVIN, A.A., and KORNBRUST, D.J. (1997d). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. 7, 473-481.
21. KOLE, R., KRAINER, A.R., and ALTMAN, S. (2012). RNA therapeutics: beyond RNA interference and antisense oligo-nucleotides. Nat. Rev. Drug Discov. 11, 125-140.
22. KOLLER, E., GAARDE, W.A., and MONIA, B.P. (2000). Elucidating cell signaling mechanisms using antisense technology. Trends Pharmacol. Sci. 21, 142-148.
23. KORTYLEWSKI, M., XIN, H., KUJAWSKI, M., LEE, H., LIU, Y., HARRIS, T., DRAKE, C., PARDOLL, D., and YU, H. (2009). Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15, 114-123.
24. LASKIN, J.J., NICHOLAS, G., LEE, C., GITLITZ, B., VINCENT, M., CORMIER, Y., STEPHENSON, J., UNG, Y., SANBORN, R., PRESSNAIL, B., et al. (2012). Phase 1/2 trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J. Thorac. Oncol. 7, 579-586.
25. LEVIN, A.A. (1999). A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleo-tides. Biochim. Biophys. Acta 1489, 69-84.
26. MONTEITH, D.K., GEARY, R.S., LEEDS, J.M., JOHNSTON, J., MONIA, B.P., and LEVIN, A.A. (1998). Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicol. Sci. 46, 365-375.
27. MONTEITH, D.K., HENRY, S.P., HOWARD, R.B., FLOURNOY, S., LEVIN, A.A., BENNETT, C.F., and CROOKE, S.T.(1997).Immune stimulation-a class effect of phosphorothioate oligodeoxy-nucleotides in rodents. Anti-Cancer Drug Design 12, 421-432.
28. MONTEITH, D.K., HORNER, M.J., GILLETT, N.A., BUTLER, M., GEARY, R.S., BURCKIN, T., USHIRO-WATANABE, T., and LEVIN, A.A. (1999). Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol. Pathol. 27, 307-317.
29. RAAL, F.J., SANTOS, R.D., BLOM, D.J., MARAIS, A.D., CHARNG, M.J., CROMWELL, W.C., LACHMANN, R.H., GAUDET, D., TAN, J.L., CHASAN-TABER, S., et al. (2010). Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375, 998-1006.
30. SARMIENTO, U.M., PEREZ, J.R., BECKER, J.M., and RAMASWA-MY, N. (1994). In vivo toxicological effects of rel A antisense phos-phorothioates in CD-1 mice. Antisense Res. Dev. 4, 99-107.
31. SENN, J.J., BUREL, S., and HENRY, S.P. (2005). Non-CpG containing antisense 2¢ MOE oligonucleotides activate a proin-flammatory response independent of TLR-9 or MyD88. J. Pharmacol. Exp. Ther. 314, 972-979.
32. SETH, P.P., SIWKOWSKI, A., ALLERSON, C.R., VASQUEZ, G., LEE, S., PRAKASH, T.P., KINBERGER, G., MIGAWA, M.T., GAUS, H., BHAT, B., et al. (2008). Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt)nucleosideanalogs. NucleicAcidsSympSer.(Oxf.), 553-554.
33. SETH, P.P., SIWKOWSKI, A., ALLERSON, C.R., VASQUEZ, G., LEE, S., PRAKASH, T.P., WANCEWICZ, E.V., WITCHELL, D., and SWAYZE, E.E. (2009). Short antisense oligonucleotides with novel 2¢-4¢ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13.
34. TALBOT, D.C., RANSON, M., DAVIES, J., LAHN, M., CALLIES, S., ANDRE, V., KADAM, S., BURGESS, M., SLAPAK, C., OLSEN, A.L., et al. (2010). Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin. Cancer Res. 16, 6150-6158.
35. YU, R.Z., BAER, B., CHAPPEL, A., GEARY, R.S., CHUENG, E., and LEVIN, A.A. (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immu-nosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal. Biochem. 304, 19-25.
36. ZHAO, Q., TEMSAMANI, J., ZHOU, R.-Z., and AGRAWAL, S. (1997). Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense and Nucleic Acid Drug Dev. 7, 495-502.